Literature DB >> 6430369

In vitro characterization of commercial Factor VIII concentrates: long-term follow-up.

C Miyashita, P Hellstern, M Köhler, G von Blohn, E Wenzel.   

Abstract

Fifty batches of Factor VIII concentrates from 12 producers were characterized in a long-term follow-up. The following parameters were measured: Factor VIII: C, Factor VIIIR: AG, Factor VIII: Rcof, specific activity (U Factor VIII: C/mg protein), fibrinogen, IgG, IgM, IgA, isoagglutinins, Hbs-AG, heparin-like activity, thrombin-like activity, antithrombin III, Factor VIII-stability at room temperature, and the rate of complete dissolution of the lyophilizate. In most preparations there was an unacceptable batch-to-batch variation of both Factor VIII complex and contaminating proteins, which exceeded the inter-assay coefficient of variation of the applied test systems. Nevertheless, different brands could be recognized by their typical protein pattern. The results obtained suggest that the standardization of Factor VIII concentrates of unknown composition is still accompanied by considerable risks.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430369     DOI: 10.1007/bf00320384

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  8 in total

1.  Characteristics of various factor VIII concentrates used in treatment of haemophilia A.

Authors:  I M Nilsson; U Hedner
Journal:  Br J Haematol       Date:  1977-12       Impact factor: 6.998

2.  Hemolytic anemia due to anti-A in concentrated antihemophilic factor preparations.

Authors:  L A Rosati; B Barnes; H A Oberman; J A Penner
Journal:  Transfusion       Date:  1970 May-Jun       Impact factor: 3.157

3.  Factor VIII standardisation.

Authors:  T W Barrowcliffe; D P Thomas
Journal:  Lancet       Date:  1981-12-12       Impact factor: 79.321

4.  Factor VIII concentrates: What the label says.

Authors:  D E Austen; I R Rhymes; C R Rizza
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

5.  Standardization of Factor VIII. I. Calibration of British Standards for Factor VIII clotting activity.

Authors:  T W Barrowcliffe; T B Kirkwood
Journal:  Br J Haematol       Date:  1980-11       Impact factor: 6.998

6.  [Side-effects of factor VIII substitution in patients with hemophilia A (author's transl)].

Authors:  V Tilsner; H Reuter
Journal:  MMW Munch Med Wochenschr       Date:  1982-06-04

7.  [Factor VIII concentrates. Problems and protein chemistry characterization].

Authors:  A Kröniger; A Kumpe; W Wormsbächer; B Herchenhahn
Journal:  Med Welt       Date:  1982-07-16

8.  Hemolysis caused by factor VIII concentrates.

Authors:  E P Orringer; M J Koury; P M Blatt; H R Roberts
Journal:  Arch Intern Med       Date:  1976-09
  8 in total
  1 in total

1.  The use of heat-treated Factor VIII-concentrates in von Willebrand's disease.

Authors:  M Köhler; P Hellstern; E Wenzel
Journal:  Blut       Date:  1985-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.